The CEO's $6.8M open-market sale at $69.33 is the largest single insider sale in the cluster and represents a meaningful reduction in his stake. While insider sales are generally weak signals, the concentration in C-suite and the cluster's timing after a period of strong analyst bullishness (89% buy) warrants caution. Monitor for any upcoming negative catalyst (data readout, regulatory update) that may have prompted the selling.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 16 $69.39entry
- T+1 · 2mo ago +0.76%α −0.37% · $69.92
- T+5 · 8w ago −5.16%α −6.98% · $65.81
- T+20 · 5w ago −8.59%α −10.65% · $63.43
- T+43 · todayOpen
- T+60 · in 23d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cytokinetics CEO Robert Blum sold $7.3M in open-market shares (97,926 shares at $69.33 and 7,500 at $73.44) alongside director Robert Landry selling $147K and EVP Fady Malik selling $264K, totaling ~$7.7M in insider sales over a 7-day window. The CEO's sales coincide with derivative exercises and gifts, but the open-market sales are material at ~0.08% of the $9.6B market cap.
Key Financial Metrics
Key Facts
- CEO Robert Blum sold 97,926 shares open-market at $69.33 for $6.79M on 2026-09-15
- CEO Blum also sold 7,500 shares at $73.44 for $551K on 2026-09-14
- EVP R&D Fady Malik sold 3,500 shares at $75.46 for $264K on 2026-09-08
- Director Robert Landry sold 1,000 shares at $72.13 and 1,000 at $74.66, total $147K
- Total open-market insider sales: ~$7.7M, representing ~0.08% of $9.6B market cap
- CEO also exercised 7,500 derivative shares at $10.60 and gifted 99,276 shares at $0
Financial Impact
Insider sales of ~$7.7M open-market, ~0.08% of market cap; non-cash gifts and exercises add no economic value
Risk Factors
- Insider sales may signal management's view that the stock is fully valued or that a catalyst is approaching
- CEO's derivative exercise and concurrent sale suggests tax-motivated liquidity rather than pure bearish view
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1789539121524 |
Track record
46 reports on CYTK
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +7.06% at T+20 after the May 8, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers